Brind.
  1. Organon and Merck are facing industry headwinds and market drawdowns following Organon's spin-off from Merck.

Organon shares returned -8.2% on August 12, 2025, while the Zacks Medical Services industry lost 2.5%.

2 reports, 1 independent Updated Aug 12
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Organon shares returned -8.2% on August 12, 2025, while the Zacks Medical Services industry lost 2.5%.

Who's involved

What this event is mainly about
Organon & Co.

How it developed

Newest first. Tap a step to see who reported it.
  1. Organon stock dropped 8.2% on Aug 12, 2025, illustrating industry headwinds.1 source
  2. Organon & Co. received a positive financial outlook update regarding estimate revisions and valuation metrics.1 source

Keep exploring

Part of

Organon and Merck are facing industry headwinds and market drawdowns following Organon's spin-off from Merck. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ZacksInvestors Heavily Search Organon & Co. (OGN): Here is What You Need to Know Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of
  • ZacksOGN vs. HQY: Which Stock Is the Better Value Option? Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is mo